Aligos Therapeutics (ALGS) vs Black Hawk Acquisition (BKHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Black Hawk Acquisition is the larger company by market cap ($7.7 million vs $7.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALGS | BKHA |
|---|---|---|
| Share price | $1.22 | $1.85 |
| Market cap | $7.62M | $7.68M |
| 1-day change | -2.40% | -71.45% |
| YTD return | -86.91% | — |
| 1-year return | -86.75% | — |
| 5-year return | -99.70% | — |
| P/E ratio (TTM) | — | 5.61 |
| EPS (TTM) | $-6.46 | $0.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.19M | — |
| Revenue growth (YoY) | -39.46% | — |
| Net income (latest FY) | $-24.19M | $1.33M |
| Operating margin | -4024.93% | — |
| Net margin | -1106.72% | — |
| 52-week high | $13.69 | $23.00 |
| 52-week low | $1.18 | $1.75 |
| Distance from 52-week high | -91.09% | -91.96% |
| Analyst consensus | none | — |
| Avg. price target upside | +4193.44% | — |
| Average volume | 57.37K | 101.40K |
| Shares outstanding | 5.45M | 4.15M |
| Employees | 82 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aligos Therapeutics
ALGS stock →Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
About Black Hawk Acquisition
BKHA stock →Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
ALGS vs BKHA FAQ
Which is bigger, Aligos Therapeutics or Black Hawk Acquisition?
Black Hawk Acquisition (BKHA) is larger, with a market capitalization of $7.68M compared with $7.62M for Aligos Therapeutics (ALGS).
Are Aligos Therapeutics and Black Hawk Acquisition in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.